Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437386 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ATMTSHRADRB2ADRB1 | |
| SCHEMBL4435346 | 0.93 | NAAA (0.39) | ALDH1A1TSHRHCAR2NAAACES2 | |
| SCHEMBL4435349 | 0.93 | NAAA (0.39) | ALDH1A1TSHRHCAR2NAAACES2 | |
| SCHEMBL4429568 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL4426661 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL23853439 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL4437718 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL4428273 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL4428272 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 | |
| SCHEMBL23853436 | 0.91 | NAAA (0.42) | TSHRHCAR2NAAACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544461-B2 | Near infrared ray activation type positive resin composition | KANSAI PAINT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7358030-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20070259279-A1 | Near Infrared Ray Activation Type Positive Resin Composition | KANSAI PAINT CO., LTD. (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-101027609-A | Positive resin composition of near-infrared-ray activation type | KANSAI PAINT CO LTD (JP) | 2007-08-29 | — | — | CN | disclosed |
| EP-1788432-A1 | POSITIVE RESIN COMPOSITION OF NEAR-INFRARED-RAY ACTIVATION TYPE | Kansai Paint Co., Ltd. (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060074262-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7015363-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040181097-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1415968-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | Kyowa Yuka Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074262-A1 | Process for producing ether compound | AGL, ARL1, CYP2C8 | ALDH1A1 1191/4885ATM 3315/4885TSHR 3842/4885 |
| US-20040181097-A1 | Process for producing ether compound | CYP2E1, ARL1, MRPL21 | ALDH1A1 902/4885ATM 4006/4885TSHR 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.